Infanrix Ipv (Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads)

The vaccine contains purified antigens from diphtheria toxin, tetanus toxoid, acellular pertussis components and inactivated poliovirus, adsorbed onto aluminium hydroxide. After intramuscular injection, antigen‑presenting cells process these proteins, activating B‑cells and T‑cells, which then generate protective antibodies that neutralize the toxins and viruses, establishing active immunity.

The dosing schedule for Infanrix IPV is determined by the prescribing healthcare professional based on national immunization guidelines. Typically, the vaccine is administered as a series of intramuscular injections at specific ages in infancy, but the exact dose and timing should be confirmed by the child's physician.

Infanrix IPV is generally not recommended for routine use in pregnant women, as safety data are limited. Women who are pregnant should discuss vaccination with their healthcare provider. The vaccine is considered compatible with breastfeeding, but mothers should consult a physician to weigh any potential risks and benefits.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, cold‑chain shipping details and required import documentation.

Infanrix IPV combines diphtheria, tetanus, acellular pertussis and inactivated poliovirus antigens in a single injection, reducing the number of separate shots required. Compared with older whole‑cell pertussis vaccines, it offers a lower reactogenicity profile while maintaining comparable protection. It is also aligned with EU‑approved immunization schedules.

Infanrix IPV must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging to protect from light, and must never be frozen or shaken. Prior to administration, the vaccine should be inspected for particulate matter or discoloration and used promptly after removal from the refrigerator.

The vaccine is given as an intramuscular injection, typically into the anterolateral thigh of infants or the deltoid muscle of older children. Administration is performed by a qualified healthcare professional using aseptic technique. The injection site should be monitored for local reactions following vaccination.

Serious adverse events are rare but may include anaphylactic reactions, seizures, high fever, prolonged crying episodes, and hypotonic‑hyporesponsive episodes. Any signs of severe allergic reaction, such as difficulty breathing, swelling of the face or throat, or hives, require immediate medical attention.

Infanrix IPV should not be administered to individuals with a known severe allergy to any vaccine component, including aluminium salts or the specific antigens. It is also contraindicated in persons with a history of severe anaphylaxis after a previous dose of a DTaP‑IPV vaccine. Consultation with a healthcare provider is essential for those with immunodeficiency or other medical concerns.